Duke Clinical Research Institute

1. AstraZeneca UK Limited $4,382,508 12 payments
2. Merck Sharp & Dohme Corporation $2,869,307 18 payments
3. AstraZeneca Pharmaceuticals LP $2,224,572 37 payments
4. E.R. Squibb & Sons, L.L.C. $1,776,785 4 payments
5. Pfizer Inc. $368,933 2 payments
6. Novo Nordisk Inc $248,600 3 payments
7. GlaxoSmithKline, LLC. $200,400 2 payments
8. Melinta Therapeutics, Inc. $108,392 3 payments
9. Olympus Corporation of the Americas $80,122 1 payment
10. Terumo Medical Corporation $75,000 1 payment

1. A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA $2,377,794 13 payments
2. Outcomes Database to prospectivelY aSSEss changing TherapY landscape in Renal Cell Carcinoma (ODYSSEY RCC) $1,776,785 4 payments
3. A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function $1,776,653 2 payments
4. A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease COPD with a History of COPD Exacerbations OBERON $1,561,239 4 payments
5. Phase III study is to evaluate the efficacy and safety of Tozorakimab MEDI3506 Dose 1 and Dose 2 administered subcutaneously SC in adult participants with symptomatic COPD and history of 2 moderate or 1 severe exacerbation of COPD in the previous 12 months $1,480,062 4 payments
6. An ImplemeNtation Study to ImProve CardIometabolic CaRE in Diabetes Mellitus (INSPIRE-D) $1,114,498 1 payment
7. Supplemental Analyses for Publication of Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study (ARTEMIS) Data Sets $295,367 2 payments
8. Developing Misinformation Web Tool Post Guidance $258,415 1 payment
9. Type 2 Diabetes, Nash and Obesity in accordance with Research Activities related to MEDI0382 program $235,018 2 payments
10. 0000000000000000000000000000000000000000000000000000000000000000217731 $200,400 2 payments

1. Other $108,392 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.